Aveanna Healthcare Holdings Inc. filings document the public-company disclosures of a home healthcare operator with pediatric and adult care services. Its 8-K reports cover operating and financial results, guidance updates, Regulation FD investor presentations, material-event disclosures, capital-structure matters, and material agreements tied to the company and its common stock.
Proxy and governance filings describe annual meeting matters, board composition, committee service, executive compensation arrangements, employment agreements, stock incentive plan matters, and stockholders agreement provisions, including transfer restrictions and ownership-guideline-related terms. The filing record also includes director transitions and governance disclosures connected to compensation, nominating and corporate governance, and clinical quality and compliance oversight.
Aveanna Healthcare Holdings, Inc. (AVAH) reports that certain existing stockholders completed a secondary public offering of its common stock. On August 20, 2026, the company and the selling stockholders entered into an Underwriting Agreement with RBC Capital Markets, LLC for the sale by those stockholders of 15,000,000 shares of Aveanna common stock at a public offering price of $11.75 per share. The selling stockholders also granted the underwriter a 30‑day option to purchase up to an additional 2,250,000 shares. The secondary offering closed on August 24, 2026. Aveanna did not issue any new shares and did not receive any proceeds from this offering; all proceeds went to the selling stockholders.
Aveanna Healthcare Holdings Inc. (AVAH) has filed a prospectus supplement for the resale by selling stockholders of 15,000,000 shares of common stock at a public offering price of $11.75 per share. Aveanna will not receive any proceeds from this secondary offering, though it will bear offering expenses other than underwriting discounts and commissions.
The selling stockholders will receive net proceeds of $11.50 per share, or $172.5 million in total, with RBC Capital Markets acting as sole underwriter and holding a 30‑day option to purchase up to 2,250,000 additional shares. Aveanna had 218,152,927 shares outstanding as of July 4, 2026. After completion, the company will no longer be a Nasdaq-defined controlled company, though Bain Capital and J.H. Whitney affiliates are expected to retain significant influence with beneficial ownership of about 44.1% of common stock. Aveanna recently expanded its Private Duty Services segment by acquiring Family First Holding, LLC, a multi-state pediatric home care provider with 27 locations in seven states.
Aveanna Healthcare Holdings Inc. (AVAH) has registered a resale offering of 15,000,000 shares of common stock, all to be sold by existing selling stockholders; Aveanna will not receive any proceeds from these sales but will pay offering expenses other than underwriting discounts and commissions.
The underwriter has a 30‑day option to purchase up to 2,250,000 additional shares from certain Whitney-affiliated stockholders. Aveanna had 218,152,927 shares outstanding as of July 4, 202644.1% of the common stock and retain significant influence.
Aveanna Healthcare Holdings reported stronger results for the three and six months ended July 4, 2026. Quarterly revenue was $670.5 million, up from $589.6 million a year earlier, with growth across Private Duty Services, Home Health & Hospice, and Medical Solutions. Q2 net income rose to $40.3 million from $27.0 million, while diluted EPS was $0.18.
For the first six months of 2026, revenue reached $1.32 billion and net income $81.9 million. Operating cash flow improved to $85.3 million, aided by lower interest expense. Cash and equivalents declined to $97.2 million from $193.3 million as the company spent $173.7 million in cash to acquire Family First Holding, expanding its pediatric home-care footprint and adding $156.2 million of goodwill.
The balance sheet shows $1.32 billion of term loans and a $165.0 million receivables securitization outstanding at quarter-end, with total liabilities of $1.82 billion. Aveanna refinanced and repriced its credit facilities, reducing interest margins, and uses interest rate caps on up to $1.40 billion of notional exposure. Subsequent to quarter-end, securitization borrowings increased to $206.3 million.
Aveanna Healthcare Holdings Inc. outlines its homecare platform, 2026 outlook and recent performance across three segments: Private Duty Services, Home Health & Hospice, and Medical Solutions. For full year 2026, management targets revenue >$2.68 billion, gross margin of 32.2% and Adjusted EBITDA >$365 million, supported by a national footprint of 403 locations in 39 states, more than 30,000 caregivers and 48.9 million annualized homecare hours.
For Q2 2026, revenue was $670.5 million, up 13.7% from Q2 2025, with gross margin of $218.5 million and Adjusted EBITDA of $95.4 million. Segment revenue growth was led by Private Duty Services at 14.0%, Home Health & Hospice at 14.8% and Medical Solutions at 9.4%, each driven primarily by higher volumes. Free cash flow for 2026 is shown as positive $75.4 million, an improvement of $38.5 million versus 2025.
Liquidity totals $432.7 million, including $97.2 million of cash, with $1,483 million of variable-rate debt partially hedged by interest rate caps. Management highlights long-term organic growth and tuck-in M&A, a large homecare market of about $183 billion TAM growing ~6.5%, and increasing use of value-based and preferred payor agreements.
Aveanna Healthcare Holdings Inc. reported strong growth for the three and six-month periods ended July 4, 2026. For the quarter, revenue was $670.5 million, up 13.7% from $589.6 million a year earlier, driven by increases across its PDS, HHH, and MS segments. Quarterly net income rose to $40.3 million (diluted EPS $0.18) from $27.0 million (EPS $0.13), while Adjusted EBITDA was $95.4 million, up 8.0%, although the Adjusted EBITDA margin declined to 14.2% from 15.0% as gross margin percentage compressed.
For the first six months, revenue reached $1,318.4 million, an increase of 14.8%, with net income of $81.9 million versus $32.2 million and Adjusted EBITDA of $179.8 million, up 15.4%. Aveanna raised its full-year 2026 outlook, guiding to revenue of more than $2.68 billion and Adjusted EBITDA of more than $365 million. As of July 4, 2026, the company held $97.2 million of cash and $1,483.4 million of total indebtedness, with additional borrowing capacity under its securitization facility and revolving credit facility.
Aveanna Healthcare Holdings Inc. announced that on August 5, 2026, Dr. Erica Schwartz, a Class III, independent director, resigned from its Board of Directors, effective immediately. Her departure is tied to her nomination and subsequent confirmation as Director of the United States Centers of Disease Control and Prevention.
The company states that Dr. Schwartz’s resignation was not due to any disagreement regarding its operations, policies, or practices. Before stepping down, she served as Chair of the Clinical Quality Committee, providing board-level oversight of clinical quality matters.
Aveanna Healthcare Holdings Inc. has large shareholders affiliated with J.H. Whitney reporting their beneficial ownership of common stock. PSA Healthcare Investment Holding LLC reports 15,523,810 shares, or 7.13% of the class, while J.H. Whitney VII, L.P. reports 10,112,123 shares, or 4.64%. Three additional J.H. Whitney–related entities hold smaller stakes ranging from 0.09% to 0.83%.
The J.H. Whitney parties and funds advised by Bain Capital Investors, LLC are parties to a Stockholders Agreement to coordinate director voting and transfers. Under Section 13(d) group rules, this combined group may be deemed to beneficially own 110,666,770 shares, or 50.82% of Aveanna’s common stock, though the reporting entities expressly disclaim beneficial ownership of shares held by the others and of any shares attributed solely by the agreement.
Aveanna Healthcare Holdings insider entities reported sizable stock sales. On June 30, 2026, investment entities associated with Robert M. Williams Jr., including J.H. Whitney VII, L.P. and related Iliad holding vehicles, sold a combined 3,000,000 shares of Aveanna common stock at $8.01 per share in open-market transactions.
After these sales, the entities continued to hold large indirect positions, such as 10,112,123 shares held by J.H. Whitney VII, L.P., 1,813,795 shares held by JHW Iliad Holdings LLC, and 190,130 shares held by JHW Iliad Holdings II LLC, with additional shares held by PSA-affiliated holding companies. Footnotes state that Williams and the managing entities may be deemed to share voting and dispositive power, but each disclaims beneficial ownership except to the extent of any pecuniary interest.
Aveanna Healthcare Holdings insider-related entities sold common stock in a sizable secondary transaction. Investment entities associated with Paul R. Vigano sold an aggregate 3,000,000 shares of Aveanna Healthcare common stock on June 30, 2026 at an average price of $8.01 per share in open-market or private transactions.
After these sales, JHW Iliad Holdings II LLC held 190,130 shares, JHW Iliad Holdings LLC held 1,813,795 shares, and J.H. Whitney VII, L.P. held 10,112,123 shares, all reported as indirect holdings. Additional indirect positions were 1,426,034 shares held by PSA Iliad Holdings LLC and 15,523,810 shares held by PSA Healthcare Investment Holdings LLC, while Vigano reported no direct holdings. Footnotes state that various J.H. Whitney-affiliated entities and Vigano may be deemed to share voting and dispositive power and each disclaims beneficial ownership except to the extent of pecuniary interest.